NICE no to GSK’s lupus drug Benlysta

NICE is still not recommending GlaxoSmithKline’s lupus drug Benlysta, as it believes the treatment is too costly.  In its final draft guidance the watchdog said it was minded not to recomme…
Read the full story: InPharm